CompletedNot applicableNCT01369719
Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
Studying Rare hereditary hemochromatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hormozgan University of Medical Sciences
- Principal Investigator
- Fariba Mansoori, ResidentHormozgan University of Medical Sciences (HUMS)
- Intervention
- osveral(drug)
- Enrollment
- 138 target
- Eligibility
- 2 years · All sexes
- Timeline
- 2010 – 2011
Study locations (1)
- Hormozgan University of Medical Sciences (HUMS), Bandar Abbas, Hormozgan, Iran
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01369719 on ClinicalTrials.govOther trials for Rare hereditary hemochromatosis
Additional recruiting or active studies for the same condition.